Dexlansoprazole Patent Expiration
Dexlansoprazole is Used for treating gastroesophageal reflux disease (GERD) and maintaining the healing of erosive esophagitis. It was first introduced by Takeda Pharmaceuticals Usa Inc
Dexlansoprazole Patents
Given below is the list of patents protecting Dexlansoprazole, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Dexilant | US9233103 | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy | Mar 05, 2032 | Takeda Pharms Usa |
| Dexilant |
US8173158 (Pediatric) | Methods of treating gastrointestinal disorders independent of the intake of food | Sep 17, 2030 | Takeda Pharms Usa |
| Dexilant | US8173158 | Methods of treating gastrointestinal disorders independent of the intake of food | Mar 17, 2030 | Takeda Pharms Usa |
| Dexilant Solutab | US9241910 | Orally-disintegrating solid preparation | Mar 10, 2029 | Takeda Pharms Usa |
| Dexilant Solutab |
US8871273 (Pediatric) | Method for producing granules | Jul 11, 2028 | Takeda Pharms Usa |
| Dexilant | US8871273 | Method for producing granules | Jan 11, 2028 | Takeda Pharms Usa |
| Dexilant Solutab | US8871273 | Method for producing granules | Jan 11, 2028 | Takeda Pharms Usa |
| Dexilant |
US8105626 (Pediatric) | Granules containing acid-unstable chemical in large amount | Mar 27, 2027 | Takeda Pharms Usa |
| Dexilant |
US7790755 (Pediatric) | Controlled release preparation | Feb 02, 2027 | Takeda Pharms Usa |
| Dexilant | US8105626 | Granules containing acid-unstable chemical in large amount | Sep 27, 2026 | Takeda Pharms Usa |
| Dexilant | US7790755 | Controlled release preparation | Aug 02, 2026 | Takeda Pharms Usa |
| Dexilant |
US8461187 (Pediatric) | Multiple PPI dosage form | Jul 17, 2026 | Takeda Pharms Usa |
| Dexilant Solutab |
US8461187 (Pediatric) | Multiple PPI dosage form | Jul 17, 2026 | Takeda Pharms Usa |
| Dexilant | US9011926 | Method for producing granules | Feb 24, 2026 | Takeda Pharms Usa |
| Dexilant Solutab | US9011926 | Method for producing granules | Feb 24, 2026 | Takeda Pharms Usa |
| Dexilant | US8461187 | Multiple PPI dosage form | Jan 17, 2026 | Takeda Pharms Usa |
| Dexilant | US9238029 | Multiple PPI dosage form | Jan 17, 2026 | Takeda Pharms Usa |
| Dexilant Solutab | US8461187 | Multiple PPI dosage form | Jan 17, 2026 | Takeda Pharms Usa |
| Dexilant Solutab | US9238029 | Multiple PPI dosage form | Jan 17, 2026 | Takeda Pharms Usa |
| Dexilant |
US8722084 (Pediatric) | Controlled release preparation |
Apr 15, 2024
(Expired) | Takeda Pharms Usa |
| Dexilant |
US8784885 (Pediatric) | Controlled release preparation |
Apr 15, 2024
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US8784885 (Pediatric) | Controlled release preparation |
Apr 15, 2024
(Expired) | Takeda Pharms Usa |
| Dexilant | US8722084 | Controlled release preparation |
Oct 15, 2023
(Expired) | Takeda Pharms Usa |
| Dexilant | US8784885 | Controlled release preparation |
Oct 15, 2023
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US8784885 | Controlled release preparation |
Oct 15, 2023
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US6664276 (Pediatric) | Benzimidazole compound crystal |
Jul 30, 2023
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US6664276 | Benzimidazole compound crystal |
Jan 30, 2023
(Expired) | Takeda Pharms Usa |
| Dexilant |
US6462058 (Pediatric) | Benzimidazole compound crystal |
Dec 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant |
US6664276 (Pediatric) | Benzimidazole compound crystal |
Dec 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant |
US6939971 (Pediatric) | Benzimidazole compound crystal |
Dec 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant |
US7285668 (Pediatric) | Process for the crystallization of (R)- or (S)-lansoprazole |
Dec 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US6462058 (Pediatric) | Benzimidazole compound crystal |
Dec 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US6939971 (Pediatric) | Benzimidazole compound crystal |
Dec 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US7285668 (Pediatric) | Process for the crystallization of (R)- or (S)-lansoprazole |
Dec 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant | US6462058 | Benzimidazole compound crystal |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant | US6664276 | Benzimidazole compound crystal |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant | US6939971 | Benzimidazole compound crystal |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant | US7285668 | Process for the crystallization of (R)- or (S)-lansoprazole |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant | US9145389 | Benzimidazole compound crystal |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US6462058 | Benzimidazole compound crystal |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US6939971 | Benzimidazole compound crystal |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US7285668 | Process for the crystallization of (R)- or (S)-lansoprazole |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US9145389 | Benzimidazole compound crystal |
Jun 15, 2020
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US6238994 (Pediatric) | Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article |
Nov 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US6328994 (Pediatric) | Orally disintegrable tablets |
Nov 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US7431942 (Pediatric) | Orally disintegrable tablets |
Nov 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US7875292 (Pediatric) | Orally disintegrable tablets |
Nov 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US6238994 | Method of creating a rough electrode (high surface area) from Ti and TiN and resulting article |
May 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US6328994 | Orally disintegrable tablets |
May 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US7431942 | Orally disintegrable tablets |
May 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US7875292 | Orally disintegrable tablets |
May 17, 2019
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab |
US7399485 (Pediatric) | Rapidly Disintegrable solid preparation |
Nov 26, 2018
(Expired) | Takeda Pharms Usa |
| Dexilant Solutab | US7399485 | Rapidly Disintegrable solid preparation |
May 26, 2018
(Expired) | Takeda Pharms Usa |
Dexlansoprazole's Family Patents
Explore Our Curated Drug Screens
Dexlansoprazole Generic API Manufacturers
Several generic applications have been filed for Dexlansoprazole. The first generic version for Dexlansoprazole was by Endo Operations Ltd and was approved on Apr 19, 2017. And the latest generic version is by Mylan Pharmaceuticals Inc and was approved on Jan 19, 2024.
Given below is the list of companies who have filed for Dexlansoprazole generic, along with the locations of their manufacturing plants worldwide.
1. ENDO OPERATIONS
Endo Operations Ltd has filed for 2 different strengths of generic version for Dexlansoprazole. Given below are the details of the strengths of this generic introduced by Endo Operations.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG | capsule, delayed release | Prescription | ORAL | AB | Apr 19, 2017 |
| 30MG | capsule, delayed release | Prescription | ORAL | AB | Jun 16, 2022 |
2. MYLAN
Mylan Pharmaceuticals Inc has filed for 2 different strengths of generic version for Dexlansoprazole. Given below are the details of the strengths of this generic introduced by Mylan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 30MG | capsule, delayed release | Prescription | ORAL | AB | Jan 19, 2024 |
| 60MG | capsule, delayed release | Prescription | ORAL | AB | Jan 19, 2024 |
Manufacturing Plant Locations New
Mylan's manufacturing plants are situated in 4 countries - United States, India, Canada, Ireland. Given below are the details of these plant locations as well as the firm names of Mylan as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
| Canada |
| |||||||||||||||||
| Ireland |
| |||||||||||||||||
3. TWI PHARMS
Twi Pharmaceuticals Inc has filed for 2 different strengths of generic version for Dexlansoprazole. Given below are the details of the strengths of this generic introduced by Twi Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 30MG | capsule, delayed release | Prescription | ORAL | AB | Sep 16, 2022 |
| 60MG | capsule, delayed release | Prescription | ORAL | AB | Sep 16, 2022 |